As per MRFR analysis, the China Diabetic Retinopathy Market Size was estimated at 517.2 (USD Million) in 2023. The China Diabetic Retinopathy Market is expected to grow from 650 (USD Million) in 2024 to 1,500 (USD Million) by 2035. The China Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 7.899% during the forecast period (2025 - 2035).
According to the Chinese National Health Commission, the rising incidence of diabetes in the population is fuelling the market for diabetic retinopathy in China. Diabetic retinopathy, a serious health issue, is becoming more common as a result of the growing number of diabetes patients and related consequences.
Increased knowledge of diabetic retinopathy among patients and medical professionals is encouraging early detection and treatment, which is helping the market grow. Additionally, government programs to improve access to healthcare and encourage eye health in diabetic individuals are driving market expansion.
The market for diabetic retinopathy in China has a lot of potential because of the development of telemedicine and improvements in medical technology, which open up new possibilities for better management and treatment. Better patient results are made possible by the emergence of innovative treatment approaches like injectable therapy and laser treatment procedures.
The expansion of the e-health industry gives producers a way to interact with consumers and healthcare professionals, increasing access to therapies. Investment in the diabetic retinopathy market is probably encouraged by China's healthcare policies, which place a strong emphasis on prevention and routine screening for problems associated with diabetes.
In recent years, there has been a discernible trend in China towards the use of AI and machine learning in diabetic retinopathy diagnosis procedures. This technology trend is improving screening accuracy and expediting diagnoses, which is crucial in a nation with such a large population.
The increased focus on efficiently managing diabetic retinopathy is also reflected in the growth of educational initiatives targeted at enhancing screening procedures and increased cooperation across healthcare organizations.
The market's overall forecast indicates that China's management of diabetic retinopathy will significantly improve in the upcoming years as awareness, technology, and healthcare policies come into alignment.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The China Diabetic Retinopathy Market is experiencing significant growth due to the alarming rise in diabetes cases within the country. According to the Chinese Diabetes Society, approximately 11.6% of the adult population in China was diagnosed with diabetes as of 2019, with projections indicating that this number could exceed 150 million by 2030.
This increase in diabetes prevalence is directly correlated with a higher incidence of diabetic retinopathy since this condition can manifest in patients with prolonged or poorly managed diabetes.
Organizations like the Chinese Center for Disease Control and Prevention are actively raising awareness about diabetes management, which will likely spur demand for diabetic retinopathy diagnostics and treatment solutions in the future.
As more than one-third of diabetic patients are likely to develop diabetic retinopathy, the market is expected to expand accordingly. The Chinese government's initiatives in healthcare reforms and funding for diabetes-related health programs further support this growth trajectory.
Technological innovation is a crucial driver for the China Diabetic Retinopathy Market. The introduction of advanced diagnostic tools such as Optical Coherence Tomography (OCT) and Telemedicine platforms is enhancing the early detection and management of diabetic retinopathy.
According to statistics from the National Health Commission of China, more than 30% of diabetic patients in urban areas have access to advanced imaging technology, making it easier for healthcare providers to detect retinal changes at earlier stages.
Companies like Haikang Technology and Canon Medical Systems are investing heavily in the Research and Development of retinal imaging technologies. The growing adoption of these technologies is expected to increase patient diagnoses and treatment demands, contributing to the market's anticipated growth.
China's healthcare expenditure has been rising steadily, which serves as a fundamental driver for the China Diabetic Retinopathy Market. The Chinese government is committed to enhancing its healthcare system, with healthcare spending projected to reach approximately 7% of the GDP by 2025 according to the National Health Commission.
This increased spending is likely to lead to more funding for eye care services and diabetic retinopathy treatment options.
Established healthcare companies, both local and international, are responding to this trend by expanding their operations and introducing new products, which will further stimulate market growth. As patient awareness increases and more resources become available for early diagnosis and treatment, the market is expected to benefit significantly.
Enhanced awareness regarding diabetic retinopathy among the Chinese population is driving the growth of the China Diabetic Retinopathy Market. Health campaigns led by the Chinese government, non-profit organizations, and medical associations have highlighted the importance of regular eye check-ups for diabetic patients.
According to the Beijing Health Bureau, targeted awareness campaigns have led to a 25% increase in patients undergoing annual eye screenings for diabetic complications over the last five years.
This uptick in awareness not only leads to early detection but also contributes to better management of the condition, increasing the demand for various treatment modalities. The collaboration among healthcare professionals, government bodies, and organizations like the World Health Organization to educate diabetics is set to further enhance this market opportunity.
The China Diabetic Retinopathy Market is primarily segmented into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR), each playing a vital role in understanding disease progression and management strategies. NPDR is identified as an earlier stage and makes up a significant portion of diagnosed cases in the region.
In China, the rise in diabetes prevalence has led to an increasing attention towards NPDR, reflecting greater public health concerns and a need for early detection methods. On the other hand, PDR represents a more advanced stage of the disorder, offering insights into a more severe impact on the retinal health of patients.
The understanding of PDR's implications has prompted healthcare systems to engage in more aggressive treatments due to its potential for irreversible vision loss. Both segments contribute to the overall landscape of diabetic retinopathy prevalence in China, whereby NPDR serves as a fundamental indicator for interventions, while PDR drives the market towards innovative therapeutic solutions.
With around 140 million diabetes patients currently in China, the urgency to address both NPDR and PDR is framed by the increasing burden of diabetic-related ocular complications. This scenario indicates that healthcare advancements and educational campaigns are essential not only in urban areas but also in rural communities to ensure comprehensive care.
The ongoing demand for effective screening, diagnosis, and treatment options underlines the importance of both NPDR and PDR as healthcare priorities within China, as they significantly influence overall patient outcomes and healthcare expenditure.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment segment of the China Diabetic Retinopathy Market features a robust landscape driven by an increasing prevalence of diabetic retinopathy among the Chinese population. This segment includes various approaches such as Pharmacological Therapies, Laser Treatment, and Surgery.
Pharmacological Therapies, often focusing on the use of anti-VEGF drugs, play a critical role in managing the disease and mitigating vision loss, making them essential in the treatment hierarchy.
Laser Treatment is prominent for its ability to precisely target retinal areas, allowing for effective management of complications, which is gaining traction among healthcare practitioners for its efficacy and lower procedural risks.
Additionally, Surgery, while less frequently utilized, remains crucial for advanced cases where other treatments have not yielded success. The integration of technology in surgical procedures and advancements in laser equipment drive innovation and effectiveness in these treatments.
The China Diabetic Retinopathy Market is expected to grow significantly, emphasizing the importance of addressing challenges such as accessibility and affordability to achieve widespread treatment.
With an increase in healthcare expenditure and the prioritization of eye care by the government, these treatment options are expected to receive considerable attention, leading to improved outcomes for patients across the country.
The China Diabetic Retinopathy Market is significantly influenced by the End-user segment, which includes Hospitals and Clinics, Ophthalmology Centers, and Research Institutes. Hospitals and Clinics play a crucial role in the early diagnosis and treatment of diabetic retinopathy, as they provide accessible healthcare services to a large population in urban and rural areas.
Ophthalmology Centers are specialized facilities that offer advanced diagnostic tools and treatments, catering to patients with varying stages of diabetic retinopathy, and are essential for ensuring comprehensive eye care.
Research Institutes contribute critical insights into the pathophysiology of diabetic retinopathy and the development of new therapies, driving innovations in the market. With the increasing prevalence of diabetes in China, the demand across these End-user categories is expected to grow, reflecting the significance of quality eye care and the promotion of effective treatment protocols.
The combination of improved healthcare infrastructure, awareness campaigns, and advances in technology further supports thriving opportunities within these segments, ultimately enhancing the overall effectiveness of managing diabetic retinopathy across the country.
The China Diabetic Retinopathy Market has witnessed significant growth and transformation in recent years, driven by a rising prevalence of diabetes and an increasing awareness of eye health in the population. This market is characterized by a competitive landscape with numerous players vying for market share, including both multinational corporations and local healthcare providers.
The heightened competition is fostering innovation in therapies and technologies aimed at the prevention and treatment of diabetic retinopathy. Factors such as regulatory changes, extensive research and development efforts, along with strategic collaborations and partnerships, are reshaping the market dynamics.
Additionally, the growing aging population and advancements in diagnostic tools are further propelling the demand for effective treatment options, making the market a focal point of investment for many companies involved in ophthalmic care.
Merck & Co. has established a notable presence in the China Diabetic Retinopathy Market, showcasing its strength through a diverse portfolio of pharmaceutical products. The company has successfully navigated regulatory approvals and conducted extensive clinical trials specific to the Chinese populace, which has enhanced its reputation among local healthcare providers.
Merck's focus on research and development has led to innovations in diabetic retinopathy treatments that align with local health needs. By leveraging its global expertise and tailoring its strategies to the Chinese market environment, Merck & Co. has secured a competitive advantage, allowing it to maintain strong relationships with healthcare professionals and institutions.
Their commitment to addressing unmet medical needs in diabetes-related eye conditions further solidifies their position in the market.
Novartis, another key player in the China Diabetic Retinopathy Market, has carved out a substantial niche with its cutting-edge products and advanced therapeutic techniques. Their flagship offerings include targeted anti-VEGF treatments that address diabetic macular edema, a common complication of diabetic retinopathy.
Novartis has strategically enhanced its market presence through partnerships with local medical institutions and participation in health initiatives aimed at educating both providers and patients about the risk factors associated with diabetic retinopathy.
The company's strengths lie in its robust pipeline of innovative therapies, aimed at improving patient outcomes and reducing the economic burden of vision loss. Additionally, Novartis has engaged in mergers and acquisitions that bolster its product portfolio and expand its reach within the Chinese market, allowing it to effectively compete in this vital and growing sector of the healthcare industry.
The China Diabetic Retinopathy Market has witnessed significant developments recently, particularly with advancements in treatment options and growing investments from major pharmaceutical companies. In October 2023, Novartis announced a new collaboration with Chengdu Kanghong Pharmaceutical Group to enhance R&D efforts for novel therapies targeted at diabetic eye diseases.
Meanwhile, Merck and Co. showcased promising data for their diabetic retinopathy treatment in clinical trials, indicating potential growth in market share. The Chinese government continues to prioritize healthcare reforms, which positively influences market viability, with increased funding for vision-related health initiatives.
The past two years have seen substantial market valuation growth among key players such as Regeneron Pharmaceuticals and Eli Lilly, attributed to rising diabetic prevalence in China, leading to greater demand for effective ocular treatments.
Although no recent mergers or acquisitions have been publicly reported among the specified companies in this domain, the overall competitive landscape remains dynamic, driven by innovation and strategic collaborations. Concerted efforts from Roche and Sanofi also focus on expanding access to therapy for patients within the increasingly prevalent diabetic retinopathy segment.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 517.2(USD Million) |
| MARKET SIZE 2024 | 650.0(USD Million) |
| MARKET SIZE 2035 | 1500.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.899% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Merck & Co, Novartis, Regeneron Pharmaceuticals, Amgen, Eli Lilly, AbbVie, Sanofi, Roche, Santen Pharmaceutical, Horizon Therapeutics, Chengdu Kanghong Pharmaceutical Group, Zhongshan Ophthalmic Center, Bayer, Pfizer, Hua Medicine |
| SEGMENTS COVERED | Type, Treatment, End User |
| KEY MARKET OPPORTUNITIES | Rising diabetic population, Advanced diagnostic technologies, Increasing healthcare expenditure, Growing awareness programs, Enhanced treatment options |
| KEY MARKET DYNAMICS | rising prevalence of diabetes, increasing geriatric population, advancements in diagnostic technologies, growing awareness of eye health, government initiatives for screening |
| COUNTRIES COVERED | China |
Frequently Asked Questions (FAQ) :
The China Diabetic Retinopathy Market is expected to be valued at 650.0 million USD in 2024.
By 2035, the market is projected to reach a valuation of 1500.0 million USD.
The expected CAGR for the China Diabetic Retinopathy Market from 2025 to 2035 is 7.899 percent.
In 2024, NPDR is valued at 390.0 million USD and PDR at 260.0 million USD.
By 2035, NPDR is expected to reach 885.0 million USD and PDR to 615.0 million USD.
Major players in the market include Merck & Co, Novartis, Regeneron Pharmaceuticals, and Amgen.
Non-Proliferative Diabetic Retinopathy (NPDR) is anticipated to hold a larger market share compared to Proliferative Diabetic Retinopathy (PDR).
Growing diabetic population and advancements in treatment options are key growth drivers for the market.
Challenges include high treatment costs and limited access to healthcare facilities in rural areas.
The current global scenario has led to increased focus on remote patient monitoring and digital health solutions impacting market dynamics.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
